HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (“Taro,” Pink Sheets: TAROF) reported today that it has received approvals from the U.S. Food and Drug Administration (“FDA”) for its Abbreviated New Drug Application (“ANDA”) for Ciclopirox Topical Solution, 8% (Nail Lacquer) (“ciclopirox nail lacquer”) and its Supplemental ANDA for Loratadine Syrup (Oral Suspension), 5 mg/5 mL (“loratadine syrup”) in a grape flavored formulation, an over-the-counter (OTC) product.
